TABLE 1.
Activities of temporin A, linezolid, vancomycin, and teicoplanin against glycopeptide-intermediately resistant S. epidermidis in a rat model
| Group | Drug for soaking grafta | Intraperitoneal preoperative drugb | Quantitative graft culture (CFU/cm2)c |
|---|---|---|---|
| Uncontaminated control | <10 | ||
| Untreated control GISE | 6.9 × 106 ± 2.1 × 106 | ||
| GISE1d | Linezolid | 3.8 × 102 ± 0.9 × 102 | |
| GISE2d | Vancomycin | 6.8 × 104 ± 1.3 × 104 | |
| GISE3d | Teicoplanin | 8.2 × 104 ± 1.5 × 104 | |
| GISE4d | Temporin A | 3.4 × 103 ± 7.9 × 102 | |
| GISE5d,e | Temporin A | Linezolid | <10 |
| GISE6d | Temporin A | Vancomycin | 6.0 × 102 ± 2.0 × 102 |
| GISE7d | Temporin A | Teicoplanin | 5.3 × 102 ± 1.8 × 102 |
a
The Dacron graft segments were soaked with 10 mg of temporin A/liter.
b
Each rat received intraperitoneally 8 mg of linezolid, 7 mg of vancomycin, or 3 mg of teicoplanin per kg.
c
Mean number ± standard deviation. The limit of detection for the method was ≤10 CFU/ml.
d
Statistically significant compared with the untreated control group GISE result.
e
Statistically significant compared with all groups.